Regenxbio (RGNX) Operating Leases (2019 - 2026)

Regenxbio's Operating Leases history runs 7 years deep, the most recent figure standing at $65.2 million for Q4 2025.

• In Q4 2025, Operating Leases fell 12.03% year-over-year to $65.2 million; the TTM figure through Dec 2025 stood at $65.2 million (down 12.03% YoY), while the FY2025 annual figure was $65.2 million, down 12.03% from the prior year.
• Operating Leases for Q4 2025 stood at $65.2 million, down from $67.4 million in the prior quarter.
• The five-year high for Operating Leases was $88.8 million in Q4 2022, with the low at $65.2 million in Q4 2025.
• The 5-year median for Operating Leases is $82.3 million (2021), against an average of $79.6 million.
• The sharpest annual moves came in 2021 and 2025: Operating Leases soared 1062.78% in 2021, then decreased 12.03% in 2025.
• Regenxbio's Operating Leases stood at $84.9 million in 2021, then climbed by 4.56% to $88.8 million in 2022, then declined by 7.41% to $82.2 million in 2023, then decreased by 9.84% to $74.1 million in 2024, then retreated by 12.03% to $65.2 million in 2025.
• Business Quant data shows RGNX's Operating Leases at $65.2 million in Q4 2025, $67.4 million in Q3 2025, and $69.6 million in Q2 2025.